From The Motley Fool · The Motley Fool Team · · 50s
Argenx Q3 2026 Earnings: 3 Key Takeaways
Argenx reports $1.7B quarterly sales and expansion plans for long-term investors.
In brief
Argenx reports $1.7B quarterly sales and expansion plans for long-term investors. Argenx achieved $1.7 billion in Q3 2026 product sales with 54% year-over-year growth in VYVGART and plans for five 2027 product launches. Originally reported by The Motley Fool.
VYVGART Sales Growth
Product revenue rose 54% year-over-year due to increased patient adoption for generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy.
“Product net sales were $1.7 billion, representing growth of 54% year-over-year and 13% quarter-over-quarter.”
Pipeline Expansion
Argenx is advancing empasiprubart for multifocal motor neuropathy and FB102 for celiac disease to reduce dependency on a single drug.
“We're advancing empasiprubart toward its first phase 3 readout in MMN. And we had positive phase 2 results for FB102 in celiac disease, just months after the Forte acquisition.”
Operating Profit
Operating profit reached $486 million as top-line gains covered higher research and development expenses.
“Operating profit reached $486 million as top-line gains covered higher research and development expenses, allowing management to fund 10 clinical-stage molecules without eroding profitability.”
2027 Product Launches
Argenx plans up to five potential product launches in 2027 to mark significant progress toward Vision 2030.
“2027 will be an important year in the evolution of argenx with 5 potential launches across our portfolio.”
What to remember
Argenx achieved $1.7 billion in Q3 2026 product sales with 54% year-over-year growth in VYVGART and plans for five 2027 product launches.
